Edition:
United States

BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

26.90USD
25 May 2018
Change (% chg)

$-0.31 (-1.14%)
Prev Close
$27.21
Open
$27.16
Day's High
$28.00
Day's Low
$26.07
Volume
3,997
Avg. Vol
4,424
52-wk High
$48.42
52-wk Low
$19.55

Chart for

About

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase... (more)

Overall

Beta: --
Market Cap(Mil.): $604.06
Shares Outstanding(Mil.): 22.46
Dividend: --
Yield (%): --

Financials

  BYSI.OQ Industry Sector
P/E (TTM): -- 238.69 33.30
EPS (TTM): -4.94 -- --
ROI: -491.42 -7.54 13.04
ROE: -467.84 -10.33 14.90

BRIEF-BeyondSpring Says Richard Brand Resigned As CFO

* BEYONDSPRING SAYS RICHARD A. BRAND RESIGNED AS CHIEF FINANCIAL OFFICER OF CO EFFECTIVE AS OF FEBRUARY 20, 2018 - SEC FILING

Feb 21 2018

BRIEF-BeyondSpring Appoints Patrick Fabbio To Board As An Independent Member

* BEYONDSPRING APPOINTS LIFE SCIENCES VETERAN PATRICK FABBIO TO BOARD OF DIRECTORS AS AN INDEPENDENT MEMBER Source text for Eikon: Further company coverage:

Jan 03 2018

BRIEF-BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin

* BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN)

Dec 14 2017

BRIEF-Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China

* BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY

Nov 30 2017

Earnings vs. Estimates